ClinicalTrials.gg
CompletedNCT04844918SURMOUNT-JUpdated Jul 16, 2024Results posted

A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease

A Phase 3 interventional study of Tirzepatide and Placebo in Obesity, sponsored by Eli Lilly and Company. Completed at 18 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-07-16.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
267
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 104 studies testing tirzepatide in Obesity — 60 open to participants now, 79 under way, 14 of them phase 3. Tirzepatide · Obesity.

Enrollment
26th of 104
267 · median 69
Started
2021
with 5 others
Phase 3
26 of 104
7 open now
Registered
9th of 104
by date
Lead sponsor
34 of 104
Eli Lilly and Company

Among the 104 studies testing tirzepatide in Obesity, this one is the 26th largest by enrollment, is one of 6 that started in 2021, is one of 26 in phase 3, and was the 9th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

60 of the 104 studies testing tirzepatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

55 more — sign in →

By country, each count listing its studies:

All 60 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies testing tirzepatide in Obesity, or all of them as a file.
02

Study summary

The main purpose of this study is to learn more about tirzepatide in participants with obesity disease. The study will also measure how Tirzepatide affects body weight with a low-calorie diet and increased physical activity. The study will last around 72 Weeks.

03

Conditions studied

  • Obesity

Keywords

  • Metabolism and Nutrition Disorder
  • Obesity Related Health Problems
  • Obesity Disease
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a of greater than or equal to ≥27 kg/m² and \<less than 35 kg/m² with at least 2 obesity-related health problems or ≥35 kg/m² with at least 1 obesity-related health problems. Health problems are IGT, hyperlipidemia, or NAFLD.
  • Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight.

Exclusion criteria

Exclusion Criteria:

  • Have diabetes.
  • Acute or chronic liver disease other than NAFLD.
  • Have a self-reported change in body weight >5 kg within 3 months prior to screening.
  • Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months.
  • Have renal impairment measured as estimated (eGFR) \<30 mL/min/1.73 m2, calculated by Japanese Society of Nephrology coefficient-modified Chronic Kidney Disease-Epidemiology equation during screening.
  • Have a known gastric emptying abnormality.
  • Have had a history of chronic or acute pancreatitis.
  • Have thyroid-stimulating hormone outside of the range of 0.4 to 6.0 micro units per milliliter (μIU/mL) at screening.
  • Have obesity induced by other endocrinologic disorders or diagnosed monogenetic or syndromic forms of obesity.
  • Have a history of significant active or unstable major depressive disorder or other severe psychiatric disorder within the last 2 years.
  • Have a cardiovascular condition within 3 months prior to randomization
  • Have a family or personal history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia Syndrome type 2.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
267 participants (actual)

Study arms

  • Experimental
    10 Milligrams (mg) Tirzepatide

    Participants received maintenance dose 10 mg with dose escalation starting from 2.5 mg, 5 mg, 7.5 mg and then 10 mg tirzepatide administered subcutaneously (SC) once weekly (QW).

    Drug: Tirzepatide

  • Experimental
    15 mg Tirzepatide

    Participants received maintenance dose 15 mg with dose escalation starting from 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and then 15 mg tirzepatide administered SC QW.

    Drug: Tirzepatide

  • Placebo comparator
    Placebo

    Participants received matching placebo administered SC QW.

    Other: Placebo

Interventions

  • Administered SC

    Also known as: LY3298176

  • OtherPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Mean Percent Change in Body Weight

    Mean percent change in body weight was measured. Least squares (LS) mean was determined using mixed model repeated measures (MMRM) model with Baseline + impaired glucose tolerance (IGT) at Screening + Hyperlipidemia at Screening + non-alcoholic fatty liver disease (NAFLD) at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

    Time frame: Baseline, 72 Weeks

  2. Percentage of Participants Who Achieve ≥5% Body Weight Reduction

    Percentage of Participants Who Achieve ≥5% Body Weight Reduction

    Time frame: Week 72

Secondary outcomes

  1. Percentage of Participants Who Had Improvement in Obesity-related Health Problems

    Percentage of participants who had improvement in obesity-related health problems

    Time frame: Week 72

  2. Change From Baseline in Fasting Glucose for Participants With IGT at Baseline

    Change from Baseline in Fasting Glucose for Participants with IGT at Baseline. LS mean was determined by MMRM model with = Baseline + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

    Time frame: Baseline, Week 72

  3. Change From Baseline in Oral Glucose Tolerance (OGTT) 2-hr Glucose for Participants With Impaired Glucose Tolerance (IGT) at Baseline

    Change from Baseline in OGTT 2-hr Glucose for Participants with IGT at Baseline. LS mean was determined by MMRM model with Baseline + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

    Time frame: Baseline, Week 72

  4. Percent Change From Baseline in Fasting Lipids [Triglycerides (TG)] for Participants With Hyperlipidemia at Baseline

    Percent Change from Baseline in Fasting Lipids TG for Participants with Hyperlipidemia at Baseline. LS mean was determined by MMRM model with log (Baseline) + NAFLD at Screening + IGT at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

    Time frame: Baseline, Week 72

  5. Percent Change From Baseline in Hepatic Fat Fraction (HFF) for Participants With Non-alcoholic Fatty Liver Disease [NAFLD]

    Percent Change from Baseline in HFF for participants diagnosed as NAFLD by MRI at Baseline. LS mean was determined by ANCOVA model with Baseline + Hyperlipidemia at Screening + IGT at Screening + Sex + Treatment (Type III sum of squares) as variables. Percent Change from Baseline in HFF for participants with NAFLD is reported. NAFLD was diagnosed by Magnetic Resonance Imaging (MRI) at Baseline. This was evaluated only for participants who were diagnosed with NAFLD at baseline by MRI.

    Time frame: Baseline, Week 72

  6. Percentage of Participants Who Achieved Improvements of IGT

    Percentage of Participants Who Achieved Improvements of IGT. This was evaluated only for participants with IGT at baseline.

    Time frame: Week 72

  7. Percentage of Participants Who Achieved Improvements of Hyperlipidemia

    Percentage of Participants Who Achieved Improvements of Hyperlipidemia. This was evaluated only for participants with hyperlipidemia at baseline.

    Time frame: Week 72

  8. Percentage of Participants Who Achieved Improvements of NAFLD

    Percentage of Participants Who Achieved Improvements of NAFLD. This was evaluated only for participants who were diagnosed as NAFLD by MRI at Baseline.

    Time frame: Week 72

  9. Percentage of Participants Who Achieve ≥10% Body Weight Reduction

    Percentage of Participants Who Achieve ≥10% body weight reduction.

    Time frame: Week 72

  10. Percentage of Participants Who Achieve ≥15% Body Weight Reduction

    Percentage of Participants Who Achieve ≥15% body weight reduction.

    Time frame: Week 72

  11. Change From Baseline in Absolute Body Weight

    Change from Baseline in Absolute Body Weight. LS mean was determined by MMRM model with Baseline + IGT at Screening + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

    Time frame: Baseline, Week 72

  12. Change From Baseline in Body Mass Index (BMI)

    Change from Baseline in BMI. LS mean was determined using MMRM model with Baseline + IGT at Screening + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

    Time frame: Baseline, Week 72

  13. Percent Change From Baseline in Visceral Adipose Tissue (VAT)

    Percent Change from Baseline in VAT. LS mean was determined by MMRM model with Baseline + IGT at Screening + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

    Time frame: Baseline, Week 72

  14. Percent Change From Baseline in Subcutaneous Adipose Tissue (SAT)

    Percent Change from Baseline in SAT. LS mean was determined by MMRM model with Baseline + IGT at Screening + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

    Time frame: Baseline, Week 72

  15. Change From Baseline in VAT/SAT Ratio

    Change from Baseline in VAT/SAT Ratio. LS mean was determined by MMRM model with Baseline + IGT at Screening + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

    Time frame: Baseline, Week 72

  16. Percentage of Participants Who Achieved VAT <100 Square Centimeter (cm²) From Baseline for Participants With VAT≥100 cm² at Baseline

    Percentage of Participants Who Achieve VAT \<100 cm² from Baseline for participants with VAT≥100 cm² at Baseline.

    Time frame: Week 72

  17. Change From Baseline in Waist Circumference

    Change from Baseline in Waist Circumference. LS mean was determined using MMRM model with = Baseline + IGT at Screening + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

    Time frame: Baseline, Week 72

  18. Change From Baseline in Hemoglobin A1c (HbA1c)

    Change from Baseline in HbA1c was assessed only for Participants with IGT at Baseline. LS mean was determined using MMRM model with = Baseline + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

    Time frame: Baseline, Week 72

  19. Change From Baseline in Fasting Insulin for Participants With IGT at Baseline

    Change from Baseline in Fasting Insulin for Participants with IGT at Baseline. LS mean was determined using MMRM model log(Baseline) + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

    Time frame: Baseline, Week 72

  20. Change From Baseline in Systolic Blood Pressure

    Change from Baseline in Systolic Blood Pressure. LS mean was determined using MMRM model with Baseline + Hyperlipidemia at Screening + NAFLD at Screening + IGT at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

    Time frame: Baseline, Week 72

  21. Change From Baseline in Diastolic Blood Pressure

    Change from Baseline in Diastolic Blood Pressure. LS mean was determined using MMRM model with Baseline + Hyperlipidemia at Screening + NAFLD at Screening + IGT at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

    Time frame: Baseline, Week 72

  22. Change From Baseline in Short Form 36 Version 2 Health Survey (SF-36v2) Acute Form Physical Functioning Domain Score

    The SF-36v2 acute form, 1-week recall assesses participants' health-related quality of life (HRQoL) on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. Information from these 8 domains is further aggregated into 2 health component summary scores: Physical Component Summary and Mental Component Summary. Items are answered on Likert scales of varying lengths. Scoring of each domain and both summary scores are norm based and presented in the form of T scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function and/or better health. Range cannot be specified in norm-based scores. LS mean was determined using ANCOVA model with Week 0 (Visit 3) + IGT at Screening + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment (Type III sum of squares) as variables.

    Time frame: Baseline, Week 72

  23. Change From Baseline in Impact of Weight on Quality-of-Life Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score

    The IWQOL Lite-CT consists of 20 items, assessing 2 primary domains of obesity related HRQoL: Physical (7 items) and Psychosocial (13 items). A 5-item subset of the Physical domain - the Physical Function composite - is also supported. Items in the Physical Function composite describe physical impacts related to general and specific physical activities. All items in the physical domain are rated on either a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better quality of life. LS mean was determined using ANCOVA model with Week 0 (Visit 3) + IGT at Screening + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment (Type III sum of squares) as variables.

    Time frame: Baseline, Week 72

  24. Change From Baseline in Euro Quality of Life Five Dimensions (EQ-5D-5L)

    The EQ-5D-5L is a standardized instrument used to measure self-reported health status of the participants. It comprises of 5 dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). There are 5 response levels (no problems, slight problems, moderate problems, severe problems, unable to perform/extreme problems). In addition to the health profile, a single health state index value can be derived based on a formula that attaches weights to each of the levels in each dimension. This index value ranges between ˂0 (where 0 is a health state equivalent to death; negative values are valued as worse than dead) to 1 (perfect health). LS mean was determined using ANCOVA model with Week 0 (Visit 3) + IGT at Screening + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment (Type III sum of squares) as variables.

    Time frame: Baseline, Week 72

07

Results

Posted Jul 16, 2024

Participant flow

267 participants were randomized in the study. However, due to good clinical practice (GCP) compliance issues identified at one of the investigative sites, all 42 participants from that site were excluded from the study analyses

Participant flow — Overall Study
Milestone10 Milligrams (mg) Tirzepatide15 mg TirzepatidePlacebo
Started889089
Received at least 1 dose of study drug (excluding the gcp compliance investigative site)737775
Completed606567
Not completed282522
Withdrew: Adverse event785
Withdrew: Physician decision010
Withdrew: Withdrawal by subject633
Withdrew: Participants excluded due to gcp compliance issue151314

Outcome measures

PrimaryMean Percent Change in Body Weight

Mean percent change in body weight was measured. Least squares (LS) mean was determined using mixed model repeated measures (MMRM) model with Baseline + impaired glucose tolerance (IGT) at Screening + Hyperlipidemia at Screening + non-alcoholic fatty liver disease (NAFLD) at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

Time frame:
Baseline, 72 Weeks
Reported as:
Least squares mean · Percent change
Mean Percent Change in Body Weight
Percent change10 mg Tirzepatide15 mg TirzepatidePlacebo
Mean Percent Change in Body Weight-17.8 ± 0.94-22.7 ± 0.90-1.7 ± 0.90
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -16.1 · 95% CI -18.7 to -13.5
  • 15 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -21.1 · 95% CI -23.6 to -18.5
PrimaryPercentage of Participants Who Achieve ≥5% Body Weight Reduction

Percentage of Participants Who Achieve ≥5% Body Weight Reduction

Time frame:
Week 72
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieve ≥5% Body Weight Reduction
Percentage of participants10 mg Tirzepatide15 mg TirzepatidePlacebo
Percentage of Participants Who Achieve ≥5% Body Weight Reduction94.3796.0520
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Odds ratio (or): 119.65 · 95% CI 29.06 to 492.67
  • 15 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Odds ratio (or): 153.57 · 95% CI 36.03 to 654.53
SecondaryPercentage of Participants Who Had Improvement in Obesity-related Health Problems

Percentage of participants who had improvement in obesity-related health problems

Time frame:
Week 72
Reported as:
Number · Percentage of participants
Percentage of Participants Who Had Improvement in Obesity-related Health Problems
Percentage of participants10 mg Tirzepatide15 mg TirzepatidePlacebo
Percentage of Participants Who Had Improvement in Obesity-related Health Problems70.079.6911.11
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 24.26 · 95% CI 8.62 to 68.28
  • 15 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 38.27 · 95% CI 13.21 to 110.89
SecondaryChange From Baseline in Fasting Glucose for Participants With IGT at Baseline

Change from Baseline in Fasting Glucose for Participants with IGT at Baseline. LS mean was determined by MMRM model with = Baseline + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · milligrams per deciliter (mg/dL)
Change From Baseline in Fasting Glucose for Participants With IGT at Baseline
milligrams per deciliter (mg/dL)10 mg Tirzepatide15 mg TirzepatidePlacebo
Change From Baseline in Fasting Glucose for Participants With IGT at Baseline-12.81 ± 1.490-10.61 ± 1.3912.19 ± 1.291
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -15.00 · 95% CI -18.91 to -11.09
  • 15 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -12.80 · 95% CI -16.56 to -9.05
SecondaryChange From Baseline in Oral Glucose Tolerance (OGTT) 2-hr Glucose for Participants With Impaired Glucose Tolerance (IGT) at Baseline

Change from Baseline in OGTT 2-hr Glucose for Participants with IGT at Baseline. LS mean was determined by MMRM model with Baseline + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · milligrams per deciliter (mg/dL)
Change From Baseline in Oral Glucose Tolerance (OGTT) 2-hr Glucose for Participants With Impaired Glucose Tolerance (IGT) at Baseline
milligrams per deciliter (mg/dL)10 mg Tirzepatide15 mg TirzepatidePlacebo
Change From Baseline in Oral Glucose Tolerance (OGTT) 2-hr Glucose for Participants With Impaired Glucose Tolerance (IGT) at Baseline-61.50 ± 5.330-70.56 ± 4.951-5.74 ± 4.612
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -55.76 · 95% CI -69.74 to -41.77
  • 15 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -64.82 · 95% CI -78.20 to -51.43
SecondaryPercent Change From Baseline in Fasting Lipids [Triglycerides (TG)] for Participants With Hyperlipidemia at Baseline

Percent Change from Baseline in Fasting Lipids TG for Participants with Hyperlipidemia at Baseline. LS mean was determined by MMRM model with log (Baseline) + NAFLD at Screening + IGT at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Fasting Lipids [Triglycerides (TG)] for Participants With Hyperlipidemia at Baseline
Percent change10 mg Tirzepatide15 mg TirzepatidePlacebo
Percent Change From Baseline in Fasting Lipids [Triglycerides (TG)] for Participants With Hyperlipidemia at Baseline-47.3 ± 3.34-50.6 ± 2.77-11.0 ± 5.14
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -40.7 · 95% CI -50.0 to -29.7
  • 15 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -44.5 · 95% CI -52.7 to -34.9
SecondaryPercent Change From Baseline in Hepatic Fat Fraction (HFF) for Participants With Non-alcoholic Fatty Liver Disease [NAFLD]

Percent Change from Baseline in HFF for participants diagnosed as NAFLD by MRI at Baseline. LS mean was determined by ANCOVA model with Baseline + Hyperlipidemia at Screening + IGT at Screening + Sex + Treatment (Type III sum of squares) as variables. Percent Change from Baseline in HFF for participants with NAFLD is reported. NAFLD was diagnosed by Magnetic Resonance Imaging (MRI) at Baseline. This was evaluated only for participants who were diagnosed with NAFLD at baseline by MRI.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Hepatic Fat Fraction (HFF) for Participants With Non-alcoholic Fatty Liver Disease [NAFLD]
Percent change10 mg Tirzepatide15 mg TirzepatidePlacebo
Percent Change From Baseline in Hepatic Fat Fraction (HFF) for Participants With Non-alcoholic Fatty Liver Disease [NAFLD]-63.9 ± 3.09-69.9 ± 2.99-19.6 ± 3.05
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · ANCOVA · p = <0.001 · Ls mean difference: -44.4 · 95% CI -53.0 to -35.7
  • 15 mg Tirzepatide vs Placebo · ANCOVA · p = <0.001 · Ls mean difference: -50.4 · 95% CI -58.8 to -41.9
SecondaryPercentage of Participants Who Achieved Improvements of IGT

Percentage of Participants Who Achieved Improvements of IGT. This was evaluated only for participants with IGT at baseline.

Time frame:
Week 72
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Improvements of IGT
Percentage of participants10 mg Tirzepatide15 mg TirzepatidePlacebo
Percentage of Participants Who Achieved Improvements of IGT92.5097.8328.0
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 25.42 · 95% CI 7.25 to 89.14
  • 15 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 70.66 · 95% CI 12.73 to 392.24
SecondaryPercentage of Participants Who Achieved Improvements of Hyperlipidemia

Percentage of Participants Who Achieved Improvements of Hyperlipidemia. This was evaluated only for participants with hyperlipidemia at baseline.

Time frame:
Week 72
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Improvements of Hyperlipidemia
Percentage of participants10 mg Tirzepatide15 mg TirzepatidePlacebo
Percentage of Participants Who Achieved Improvements of Hyperlipidemia72.4181.0825
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 9.29 · 95% CI 2.86 to 30.20
  • 15 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 15.67 · 95% CI 4.78 to 51.37
SecondaryPercentage of Participants Who Achieved Improvements of NAFLD

Percentage of Participants Who Achieved Improvements of NAFLD. This was evaluated only for participants who were diagnosed as NAFLD by MRI at Baseline.

Time frame:
Week 72
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Improvements of NAFLD
Percentage of participants10 mg Tirzepatide15 mg TirzepatidePlacebo
Percentage of Participants Who Achieved Improvements of NAFLD69.4977.429.84
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 27.50 · 95% CI 9.35 to 80.88
  • 15 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 40.01 · 95% CI 13.27 to 120.57
SecondaryPercentage of Participants Who Achieve ≥10% Body Weight Reduction

Percentage of Participants Who Achieve ≥10% body weight reduction.

Time frame:
Week 72
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieve ≥10% Body Weight Reduction
Percentage of participants10 mg Tirzepatide15 mg TirzepatidePlacebo
Percentage of Participants Who Achieve ≥10% Body Weight Reduction85.9292.114
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 185.92 · 95% CI 46.39 to 745.16
  • 15 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 318.02 · 95% CI 74.49 to 1357.79
SecondaryPercentage of Participants Who Achieve ≥15% Body Weight Reduction

Percentage of Participants Who Achieve ≥15% body weight reduction.

Time frame:
Week 72
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieve ≥15% Body Weight Reduction
Percentage of participants10 mg Tirzepatide15 mg TirzepatidePlacebo
Percentage of Participants Who Achieve ≥15% Body Weight Reduction63.3882.891.33
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 100.21 · 95% CI 18.64 to 538.74
  • 15 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 286.73 · 95% CI 50.68 to 1622.06
SecondaryChange From Baseline in Absolute Body Weight

Change from Baseline in Absolute Body Weight. LS mean was determined by MMRM model with Baseline + IGT at Screening + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · kilograms (kg)
Change From Baseline in Absolute Body Weight
kilograms (kg)10 mg Tirzepatide15 mg TirzepatidePlacebo
Change From Baseline in Absolute Body Weight-16.0 ± 0.86-20.8 ± 0.82-1.5 ± 0.82
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -14.5 · 95% CI -16.8 to -12.2
  • 15 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -19.3 · 95% CI -21.6 to -17.0
SecondaryChange From Baseline in Body Mass Index (BMI)

Change from Baseline in BMI. LS mean was determined using MMRM model with Baseline + IGT at Screening + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · kilograms per metres squared (kg/m^2)
Change From Baseline in Body Mass Index (BMI)
kilograms per metres squared (kg/m^2)10 mg Tirzepatide15 mg TirzepatidePlacebo
Change From Baseline in Body Mass Index (BMI)-5.8 ± 0.32-7.7 ± 0.30-0.6 ± 0.30
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -5.2 · 95% CI -6.1 to -4.4
  • 15 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -7.1 · 95% CI -8.0 to -6.3
SecondaryPercent Change From Baseline in Visceral Adipose Tissue (VAT)

Percent Change from Baseline in VAT. LS mean was determined by MMRM model with Baseline + IGT at Screening + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Visceral Adipose Tissue (VAT)
Percent change10 mg Tirzepatide15 mg TirzepatidePlacebo
Percent Change From Baseline in Visceral Adipose Tissue (VAT)-39.4 ± 2.44-44.5 ± 2.37-3.4 ± 2.42
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -36.1 · 95% CI -42.9 to -29.3
  • 15 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -41.1 · 95% CI -47.8 to -34.4
SecondaryPercent Change From Baseline in Subcutaneous Adipose Tissue (SAT)

Percent Change from Baseline in SAT. LS mean was determined by MMRM model with Baseline + IGT at Screening + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Subcutaneous Adipose Tissue (SAT)
Percent change10 mg Tirzepatide15 mg TirzepatidePlacebo
Percent Change From Baseline in Subcutaneous Adipose Tissue (SAT)-32.2 ± 1.90-36.5 ± 1.85-5.0 ± 1.90
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -27.2 · 95% CI -32.6 to -21.9
  • 15 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -31.5 · 95% CI -36.7 to -26.2
SecondaryChange From Baseline in VAT/SAT Ratio

Change from Baseline in VAT/SAT Ratio. LS mean was determined by MMRM model with Baseline + IGT at Screening + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · ratio
Change From Baseline in VAT/SAT Ratio
ratio10 mg Tirzepatide15 mg TirzepatidePlacebo
Change From Baseline in VAT/SAT Ratio-0.09 ± 0.023-0.08 ± 0.0230.01 ± 0.023
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = 0.004 · Ls mean difference: -0.10 · 95% CI -0.16 to -0.03
  • 15 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = 0.006 · Ls mean difference: -0.09 · 95% CI -0.15 to -0.03
SecondaryPercentage of Participants Who Achieved VAT <100 Square Centimeter (cm²) From Baseline for Participants With VAT≥100 cm² at Baseline

Percentage of Participants Who Achieve VAT \<100 cm² from Baseline for participants with VAT≥100 cm² at Baseline.

Time frame:
Week 72
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved VAT <100 Square Centimeter (cm²) From Baseline for Participants With VAT≥100 cm² at Baseline
Percentage of participants10 mg Tirzepatide15 mg TirzepatidePlacebo
Percentage of Participants Who Achieved VAT <100 Square Centimeter (cm²) From Baseline for Participants With VAT≥100 cm² at Baseline26.3237.101.64
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 28.52 · 95% CI 4.31 to 188.55
  • 15 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 57.73 · 95% CI 8.68 to 383.88
SecondaryChange From Baseline in Waist Circumference

Change from Baseline in Waist Circumference. LS mean was determined using MMRM model with = Baseline + IGT at Screening + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · centimeters (cm)
Change From Baseline in Waist Circumference
centimeters (cm)10 mg Tirzepatide15 mg TirzepatidePlacebo
Change From Baseline in Waist Circumference-12.7 ± 0.88-16.6 ± 0.83-1.3 ± 0.84
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -11.4 · 95% CI -13.8 to -9.0
  • 15 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -15.3 · 95% CI -17.7 to -13.0
SecondaryChange From Baseline in Hemoglobin A1c (HbA1c)

Change from Baseline in HbA1c was assessed only for Participants with IGT at Baseline. LS mean was determined using MMRM model with = Baseline + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · Percentage of HbA1c
Change From Baseline in Hemoglobin A1c (HbA1c)
Percentage of HbA1c10 mg Tirzepatide15 mg TirzepatidePlacebo
Change From Baseline in Hemoglobin A1c (HbA1c)-0.67 ± 0.045-0.68 ± 0.042-0.02 ± 0.039
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -0.65 · 95% CI -0.77 to -0.53
  • 15 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -0.66 · 95% CI -0.77 to -0.55
SecondaryChange From Baseline in Fasting Insulin for Participants With IGT at Baseline

Change from Baseline in Fasting Insulin for Participants with IGT at Baseline. LS mean was determined using MMRM model log(Baseline) + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · milli-international units/liter (mIU/L)
Change From Baseline in Fasting Insulin for Participants With IGT at Baseline
milli-international units/liter (mIU/L)10 mg Tirzepatide15 mg TirzepatidePlacebo
Change From Baseline in Fasting Insulin for Participants With IGT at Baseline-6.04 ± 0.517-6.69 ± 0.433-2.13 ± 0.776
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · Ls mean difference: -3.91 · 95% CI -5.74 to -2.08
  • 15 mg Tirzepatide vs Placebo · Ls mean difference: -4.55 · 95% CI -6.29 to -2.81
SecondaryChange From Baseline in Systolic Blood Pressure

Change from Baseline in Systolic Blood Pressure. LS mean was determined using MMRM model with Baseline + Hyperlipidemia at Screening + NAFLD at Screening + IGT at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · millimeters of Mercury (mmHg)
Change From Baseline in Systolic Blood Pressure
millimeters of Mercury (mmHg)10 mg Tirzepatide15 mg TirzepatidePlacebo
Change From Baseline in Systolic Blood Pressure-11.2 ± 1.42-12.0 ± 1.351.9 ± 1.35
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -13.2 · 95% CI -17.0 to -9.3
  • 15 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -13.9 · 95% CI -17.7 to -10.1
SecondaryChange From Baseline in Diastolic Blood Pressure

Change from Baseline in Diastolic Blood Pressure. LS mean was determined using MMRM model with Baseline + Hyperlipidemia at Screening + NAFLD at Screening + IGT at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · millimeters of Mercury (mmHg)
Change From Baseline in Diastolic Blood Pressure
millimeters of Mercury (mmHg)10 mg Tirzepatide15 mg TirzepatidePlacebo
Change From Baseline in Diastolic Blood Pressure-5.9 ± 1.09-6.3 ± 1.040.5 ± 1.04
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -6.3 · 95% CI -9.3 to -3.4
  • 15 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -6.8 · 95% CI -9.7 to -3.9
SecondaryChange From Baseline in Short Form 36 Version 2 Health Survey (SF-36v2) Acute Form Physical Functioning Domain Score

The SF-36v2 acute form, 1-week recall assesses participants' health-related quality of life (HRQoL) on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. Information from these 8 domains is further aggregated into 2 health component summary scores: Physical Component Summary and Mental Component Summary. Items are answered on Likert scales of varying lengths. Scoring of each domain and both summary scores are norm based and presented in the form of T scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function and/or better health. Range cannot be specified in norm-based scores. LS mean was determined using ANCOVA model with Week 0 (Visit 3) + IGT at Screening + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment (Type III sum of squares) as variables.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Short Form 36 Version 2 Health Survey (SF-36v2) Acute Form Physical Functioning Domain Score
Score on a scale10 mg Tirzepatide15 mg TirzepatidePlacebo
Change From Baseline in Short Form 36 Version 2 Health Survey (SF-36v2) Acute Form Physical Functioning Domain Score1.1 ± 0.392.0 ± 0.37-0.1 ± 0.37
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · ANCOVA · p = 0.022 · Ls mean difference: 1.3 · 95% CI 0.2 to 2.3
  • 15 mg Tirzepatide vs Placebo · ANCOVA · p = <0.001 · Ls mean difference: 2.1 · 95% CI 1.1 to 3.2
SecondaryChange From Baseline in Impact of Weight on Quality-of-Life Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score

The IWQOL Lite-CT consists of 20 items, assessing 2 primary domains of obesity related HRQoL: Physical (7 items) and Psychosocial (13 items). A 5-item subset of the Physical domain - the Physical Function composite - is also supported. Items in the Physical Function composite describe physical impacts related to general and specific physical activities. All items in the physical domain are rated on either a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better quality of life. LS mean was determined using ANCOVA model with Week 0 (Visit 3) + IGT at Screening + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment (Type III sum of squares) as variables.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Impact of Weight on Quality-of-Life Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score
Score on a scale10 mg Tirzepatide15 mg TirzepatidePlacebo
Change From Baseline in Impact of Weight on Quality-of-Life Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score15.2 ± 2.0513.0 ± 1.952.2 ± 1.96
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · ANCOVA · p = <0.001 · Ls mean difference: 13.0 · 95% CI 7.4 to 18.7
  • 15 mg Tirzepatide vs Placebo · ANCOVA · p = <0.001 · Ls mean difference: 10.8 · 95% CI 5.4 to 16.3
SecondaryChange From Baseline in Euro Quality of Life Five Dimensions (EQ-5D-5L)

The EQ-5D-5L is a standardized instrument used to measure self-reported health status of the participants. It comprises of 5 dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). There are 5 response levels (no problems, slight problems, moderate problems, severe problems, unable to perform/extreme problems). In addition to the health profile, a single health state index value can be derived based on a formula that attaches weights to each of the levels in each dimension. This index value ranges between ˂0 (where 0 is a health state equivalent to death; negative values are valued as worse than dead) to 1 (perfect health). LS mean was determined using ANCOVA model with Week 0 (Visit 3) + IGT at Screening + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment (Type III sum of squares) as variables.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Euro Quality of Life Five Dimensions (EQ-5D-5L)
Score on a scale10 mg Tirzepatide15 mg TirzepatidePlacebo
Change From Baseline in Euro Quality of Life Five Dimensions (EQ-5D-5L)0.01 ± 0.0110.01 ± 0.011-0.01 ± 0.011
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · ANCOVA · p = 0.099 · Ls mean difference: 0.03 · 95% CI 0.00 to 0.06
  • 15 mg Tirzepatide vs Placebo · ANCOVA · p = 0.236 · Ls mean difference: 0.02 · 95% CI -0.01 to 0.05

Adverse events

Collected over Baseline Through Safety Follow-Up (Up To 76 Weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
10 mg Tirzepatide0/73 (0%)8/73 (11%)59/73 (80.8%)
15 mg Tirzepatide0/77 (0%)5/77 (6.5%)65/77 (84.4%)
Placebo0/75 (0%)5/75 (6.7%)51/75 (68%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
Event10 mg Tirzepatide15 mg TirzepatidePlacebo
Endometrial adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/301/320/30
Uterine cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/301/320/30
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/430/450/45
Benign prostatic hyperplasiaReproductive system and breast disorders0/430/451/45
Rhegmatogenous retinal detachmentEye disorders1/730/770/75
Large intestine polypGastrointestinal disorders1/730/770/75
Covid-19Infections and infestations1/730/770/75
GastroenteritisInfections and infestations1/730/770/75
Pneumonia bacterialInfections and infestations1/730/770/75
Brain stem infarctionNervous system disorders1/730/770/75
Most frequent other events
Showing 10 of 201
Most frequent other events
Event10 mg Tirzepatide15 mg TirzepatidePlacebo
ConstipationGastrointestinal disorders12/7321/775/75
NauseaGastrointestinal disorders10/7318/773/75
Covid-19Infections and infestations15/7315/7713/75
PyrexiaGeneral disorders10/7311/7711/75
DiarrhoeaGastrointestinal disorders9/737/773/75
Decreased appetiteMetabolism and nutrition disorders9/736/771/75
VomitingGastrointestinal disorders5/739/773/75
NasopharyngitisInfections and infestations7/731/778/75
Abdominal discomfortGastrointestinal disorders5/734/770/75
HeadacheNervous system disorders2/732/775/75

Baseline characteristics

All participants, excluding the GCP compliance investigative site, who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)10 mg Tirzepatide15 mg TirzepatidePlaceboTotal
Mean49.00 ± 10.8751.10 ± 10.3052.30 ± 10.9350.80 ± 10.74
Sex: Female, Male
Sex: Female, Male(Participants)10 mg Tirzepatide15 mg TirzepatidePlaceboTotal
Female30323092
Male434545133
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)10 mg Tirzepatide15 mg TirzepatidePlaceboTotal
Hispanic or Latino0000
Not Hispanic or Latino0000
Unknown or Not Reported737775225
Race (NIH/OMB)
Race (NIH/OMB)(Participants)10 mg Tirzepatide15 mg TirzepatidePlaceboTotal
American Indian or Alaska Native0000
Asian737775225
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)10 mg Tirzepatide15 mg TirzepatidePlaceboTotal
Japan737775225
08

Study locations

18 sites
  • Kohnodai Hospital, National Center for Global Health and Medicine
    Ichikawa, Chiba 272-8516, Japan
  • Saiseikai Matsuyama Hospital
    Matsuyama, Ehime 791-8026, Japan
  • Takai Internal Medicine Clinic
    Kamakura-shi, Kanagawa 247-0056, Japan
  • Motomachi Takatsuka Naika Clinic
    Yokohama-city, Kanagawa 231-0023, Japan
  • Saiseikai Yokohamashi Tobu Hospital
    Yokohama, Kanagawa 2308765, Japan
  • Medical Corporation Heishinkai OCROM Clinic
    Suita-shi, Osaka 565-0853, Japan
  • Osaka Saiseikai Suita hospital
    Suita, Osaka 564-0013, Japan
  • Takatsuki Red Cross Hospital
    Takatsuki, Osaka 569-1045, Japan
  • The Institute for Adult Disease, Asahi Life Foundation
    Chuo-ku, Tokyo 103-0002, Japan
  • Tokyo-Eki Center-building Clinic
    Chuo-ku, Tokyo 103-0027, Japan
  • Medical Corporation Chiseikai Tokyo Center Clinic
    Chuo-ku, Tokyo 103-0028, Japan
  • Fukuwa Clinic
    Chuo-ku, Tokyo 104-0031, Japan
  • Saiseikai Central Hospital
    Minato-Ku, Tokyo 108-0073, Japan
  • Shimokitazawa Tomo Clinic
    Setagaya-ku, Tokyo 155-0031, Japan
  • Miho Clinic
    Shinagawa-ku, Tokyo 141 0032, Japan
  • Medical Corporation Heishinkai ToCROM Clinic
    Shinjuku-ku, Tokyo 160 0008, Japan
  • Yamagata Tokushukai Hospital
    Yamagata-shi, Yamagata 990-0834, Japan
  • AMC Nishiumeda Clinic
    Osaka, 530-0001, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Jun 2023, 25 months.

Results were first posted in Jul 2024, 1 year after primary completion.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 25 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2021
First posted
Apr 14, 2021
StartActual
May 10, 2021
Primary completionActual
Jun 24, 2023
CompletionActual
Jun 24, 2023
Results first posted
Jul 16, 2024
Last update
Jul 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04844918
Responsible party
Sponsor
First posted
Apr 14, 2021
Start date
May 10, 2021
Primary completion
Jun 24, 2023
Completion
Jun 24, 2023
Results posted
Jul 16, 2024
Last update
Jul 16, 2024

Study contacts

Call 1-877-CTLilly (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT -5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion